November 27, 2017
KalGene Pharmaceuticals announced today the closing of a Series A financing for their Alzheimer’s drug program and to support the development of their lead therapeutic compound. The Institute supports KalGene through a collaborative project with Dr. Rosa Neto of McGill University, funded through the Early Phase Clinical Trials 2015 program.
The investment was led by Lumira Capital, and supported by Accel-Rx and others.
Read about Dr. Rosa Neto’s Institute-funded work.
Read the full press release here.